Microtubule-destabilizing SARS-CoV-2 Drug clears Phase III

Sabizabulin (VERU-111), an novel microtubule inhibitor, significantly reduced mortality in hospitalized patients with moderate to severe Covid-19 at high risk for acute respiratory distress syndrome and death according to an interim analysis from a randomized, global phase 3 clinical trial published this week in The New England Journal of Medicine Evidence.

Microtubule-destabilizing SARS-CoV-2 Drug clears Phase III Read More ยป